SCHEMBL30869417

SCHEMBL30869417

Cc1cc2c(cc1-c1ccc3[nH]ncc3c1)Oc1cc(-c3ccc4[nH]ncc4c3)cnc1N2CCCCCN1CC2(COC2)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 2/20 0.36
MAP3K11 Q16584 1/20 0.35
TNIK Q9UKE5 1/20 0.35
TRPA1 O75762 2/20 0.34
CHRNA7 P36544 2/20 0.34
ROCK2 O75116 3/20 0.33
ROCK1 Q13464 3/20 0.33
EGFR P00533 2/20 0.33
KCNH2 Q12809 1/20 0.33
BACE1 P56817 1/20 0.32
MAP4K4 O95819 1/20 0.32
ERBB2 P04626 1/20 0.32
MAPK9 P45984 1/20 0.32
CSNK1D P48730 1/20 0.32
PRKD2 Q9BZL6 1/20 0.32
SLK Q9H2G2 1/20 0.32
MAPK14 Q16539 2/20 0.31
MAPKAPK2 P49137 1/20 0.31
LRRK2 Q5S007 1/20 0.31
BRD4 O60885 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30869623 0.99 GRIA1 (0.36) GRIA1MAP3K11TNIKTRPA1CHRNA7
SCHEMBL30869716 0.98 GRIA1 (0.36) GRIA1MAP3K11TNIKTRPA1CHRNA7
SCHEMBL30869751 0.93 GRIA1 (0.35) GRIA1MAP3K11TNIKTRPA1CHRNA7
SCHEMBL30869642 0.91 EGFR (0.35) GRIA1MAP3K11TNIKTRPA1CHRNA7
SCHEMBL30869809 0.91 GRIA1 (0.39) GRIA1MAP3K11TNIKCHRNA7ROCK2
SCHEMBL30869676 0.90 GRIA1 (0.40) GRIA1MAP3K11TNIKCHRNA7ROCK2
SCHEMBL30869699 0.90 GRIA1 (0.42) GRIA1MAP3K11TNIKCHRNA7ROCK2
SCHEMBL30869508 0.89 GRIA1 (0.42) GRIA1MAP3K11TNIKCHRNA7ROCK2
SCHEMBL30869481 0.89 EGFR (0.44) GRIA1MAP3K11TNIKTRPA1CHRNA7
SCHEMBL30869804 0.88 GRIA1 (0.42) GRIA1MAP3K11TNIKCHRNA7ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070880-A1 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES, INC. (US) 2026-03-12 US disclosed
EP-4583868-A2 DYNAMIN ACTIVATORS Walden Biosciences, Inc. (US) 2025-07-16 EP disclosed
WO-2024054661-A2 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES (US) 2024-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070880-A1 DYNAMIN ACTIVATORS DNM1, DNM1L, DNM2 GRIA1 484/4885MAP3K11 2209/4885TNIK 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.